409 related articles for article (PubMed ID: 21643519)
1. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.
Engel AL; Holt GE; Lu H
Expert Rev Clin Pharmacol; 2011 Mar; 4(2):275-89. PubMed ID: 21643519
[TBL] [Abstract][Full Text] [Related]
2. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
Front Immunol; 2020; 11():1112. PubMed ID: 32595636
[TBL] [Abstract][Full Text] [Related]
3. Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines.
Fujita Y; Taguchi H
Ther Deliv; 2012 Jun; 3(6):749-60. PubMed ID: 22838070
[TBL] [Abstract][Full Text] [Related]
4. Clinical investigations of Toll-like receptor agonists.
Meyer T; Stockfleth E
Expert Opin Investig Drugs; 2008 Jul; 17(7):1051-65. PubMed ID: 18549341
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines.
Mitchell D; Yong M; Raju J; Willemsen N; Black M; Trent A; Tirrell M; Olive C
Hum Vaccin; 2011; 7 Suppl():85-93. PubMed ID: 21245658
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor agonists in cancer therapy.
Adams S
Immunotherapy; 2009 Nov; 1(6):949-64. PubMed ID: 20563267
[TBL] [Abstract][Full Text] [Related]
7. Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
Lee SN; Jin SM; Shin HS; Lim YT
Acc Chem Res; 2020 Oct; 53(10):2081-2093. PubMed ID: 32966047
[TBL] [Abstract][Full Text] [Related]
8. Reduction of avian influenza virus shedding by administration of Toll-like receptor ligands to chickens.
Barjesteh N; Shojadoost B; Brisbin JT; Emam M; Hodgins DC; Nagy É; Sharif S
Vaccine; 2015 Sep; 33(38):4843-9. PubMed ID: 26238721
[TBL] [Abstract][Full Text] [Related]
9. Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics.
Gomariz RP; Gutiérrez-Cañas I; Arranz A; Carrión M; Juarranz Y; Leceta J; Martínez C
Curr Pharm Des; 2010; 16(9):1063-80. PubMed ID: 20030612
[TBL] [Abstract][Full Text] [Related]
10. Toll-like Receptor Agonist Conjugation: A Chemical Perspective.
Ignacio BJ; Albin TJ; Esser-Kahn AP; Verdoes M
Bioconjug Chem; 2018 Mar; 29(3):587-603. PubMed ID: 29378134
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic and therapeutic implications of toll-like receptor ligands.
Hedayat M; Takeda K; Rezaei N
Med Res Rev; 2012 Mar; 32(2):294-325. PubMed ID: 22383179
[TBL] [Abstract][Full Text] [Related]
13. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.
Chakraborty S; Ye J; Wang H; Sun M; Zhang Y; Sang X; Zhuang Z
Front Immunol; 2023; 14():1227833. PubMed ID: 37936697
[TBL] [Abstract][Full Text] [Related]
14. Directing the immune system with chemical compounds.
Mancini RJ; Stutts L; Ryu KA; Tom JK; Esser-Kahn AP
ACS Chem Biol; 2014 May; 9(5):1075-85. PubMed ID: 24690004
[TBL] [Abstract][Full Text] [Related]
15. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond.
Lahiri A; Das P; Chakravortty D
Vaccine; 2008 Dec; 26(52):6777-83. PubMed ID: 18835576
[TBL] [Abstract][Full Text] [Related]
16. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.
Arsenault RJ; Kogut MH; He H
Cell Signal; 2013 Nov; 25(11):2246-54. PubMed ID: 23876795
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.
Baxevanis CN; Voutsas IF; Tsitsilonis OE
Immunotherapy; 2013 May; 5(5):497-511. PubMed ID: 23638745
[TBL] [Abstract][Full Text] [Related]
18. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).
Weeratna RD; Makinen SR; McCluskie MJ; Davis HL
Vaccine; 2005 Nov; 23(45):5263-70. PubMed ID: 16081189
[TBL] [Abstract][Full Text] [Related]
19. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.
Kaur A; Kannan D; Mehta SK; Singh S; Salunke DB
Expert Opin Ther Pat; 2018 Nov; 28(11):837-847. PubMed ID: 30280939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
